Kyto Biopharma, Inc. Announces High-Affinity Monoclonal Antibody to the Cellular Receptor for Transcobalamin (Vitamin B12)
12/3/2009 11:06:12 AM
TORONTO--(BUSINESS WIRE)--Kyto Biopharma Inc. (OTCBB: KBPH), is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.
comments powered by